8-K: Clene Inc. Announces Positive Remyelination and Neuronal Repair Data with CNM-Au8 in VISIONARY-MS Trial

Clene Inc. reports evidence of remyelination and neuronal repair with CNM-Au8 treatment in multiple sclerosis patients from the long-term extension of the Phase 2 VISIONARY-MS clinical trial.

Summary

• Clene Inc. announced positive results from the long-term open-label extension (LTE) of the Phase 2 VISIONARY-MS clinical trial.
• The data shows evidence of remyelination and neuronal repair in multiple sclerosis (MS) patients treated with CNM-Au8.
• Analyses of MRI and VEP data confirm anatomical and physiological improvements.
• Over 90% of participants who showed improvements in cognition and vision also demonstrated corresponding improvements on MRI and visual electrophysiology tests.
• The presentation took place at the American Academy of Neurology Late-Breaking Science Session.
• The study highlights significant improvements in cognition and visual function, supported by objective biomarkers like MRI Diffusion Tensor Imaging (DTI) and multi-focal Visual Evoked Potential (mf-VEP) assessments.
• 96% of participants showing visual improvement also demonstrated improvement in MRI DTI metrics.
• 91% of visual responders exhibited mf-VEP improvements.
• 98% of SDMT responders with improved cognition had corresponding improvements in MRI DTI metrics.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results, suggesting potential for a new treatment in a challenging disease area. The correlation between clinical improvements and objective biomarkers strengthens the positive outlook.

Positives

• CNM-Au8 treatment demonstrates clinical improvements in cognition and visual function in MS patients.
• Objective biomarkers (MRI DTI and mf-VEP) support the clinical improvements, indicating tissue repair and remyelination.
• The results are consistent with previous neuronal and clinical improvement observed in the double-blind period of the VISIONARY-MS trial.
• The study reinforces the long-term benefits of CNM-Au8's therapeutic mechanism.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• The actual results may differ materially from those expressed or implied by these statements.
• Risks include the ability to demonstrate the efficacy and safety of drug candidates, regulatory agency actions, and the ability to obtain additional funding.

Future Outlook

Clene looks forward to confirming these data in a global Phase 3 trial.

Management Comments

• Ben Greenberg, MS expert and Head of Medical for Clene, stated that the CNM-Au8 treatment in the Phase 2 VISIONARY-MS Trial not only led to clinical improvements, but also demonstrates that these observed clinical benefits resulted from underlying tissue repair and evidence of remyelination.

Industry Context

The press release highlights the challenges in developing remyelination therapies for MS, noting that previous attempts have had limited success in demonstrating consistent clinical benefits alongside changes in MRI or physiology measures. Clene positions CNM-Au8 as a potential breakthrough in this area.

Comparison to Industry Standards

• The press release claims that the clinical improvements correlated with objective biomarker measurements, which is not previously documented in MS clinical trials of other repair candidate drugs.
• The company claims that for years there have been attempts to test potential remyelination therapies in MS with little to no success.
• The company claims that even for interventions that yielded nominal changes in MRI or physiology measures, there was a lack of consistent, robust clinical benefits to participants.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• MS patients could benefit from a new treatment option.
• Employees may experience increased job security and growth opportunities.

Next Steps

• Clene plans to conduct a global Phase 3 trial to confirm the data.

Key Dates

Keywords

CNM-Au8, remyelination, neuronal repair, multiple sclerosis, VISIONARY-MS, clinical trial, Clene, neurodegenerative diseases, MRI, VEP